Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to Globaldata, it is involved in 13 clinical trials, of which 9 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pelacarsen Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Pelacarsen Sodium is expected to reach an annual total of $128 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Pelacarsen Sodium Overview

Pelacarsen sodium (IONIS-APOALRx) is under development for the treatment of cardiovascular diseases, aortic valve stenosis and hyperlipoproteinemia. It is administered by subcutaneous route as a solution for injectionThe drug candidate is a LICA-conjugated antisense drug. It acts by targeting the apolipoprotein (a) protein. The drug candidate is a new molecular entity (NME).

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% over FY2021. In FY2022, the company’s operating margin was 17.8%, compared to an operating margin of 22.1% in FY2021. In FY2022, the company recorded a net margin of 13.4%, compared to a net margin of 45.4% in FY2021. The company reported revenues of US$13,936 million for the second quarter ended June 2023, an increase of 5.5% over the previous quarter.

For a complete picture of Pelacarsen Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.